# Recursion Pharmaceuticals Inc. (RXRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.63, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Recursion Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 35.5×**. Each dollar of revenue is priced at 35.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.1×**. The shares trade at 2.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -18.1%** (5-yr avg -14.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -991.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -863.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -57.0%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -105.8%**. Return on all capital, debt included, is -105.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -35.2%**. Each dollar of assets produces -35.2% of profit.

## Growth
- **Revenue growth (1 yr): 26.9%** (3-yr 23.3%/yr, 5-yr 79.9%/yr). Revenue grew 26.9% over the last year, against 79.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 14.8%**. Earnings per share rose 14.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.6×**. It would take 1.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 5.50** (quick 5.50). Current assets cover the next year's liabilities 5.50 times.
- **Altman Z-score: 3.62**. A Z-score of 3.62 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Recursion Pharmaceuticals Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -19.7%** (YTD -11.2%, 3-mo 9.5%). The shares are down 19.7% over twelve months including dividends.
- **From 52-week high: -49.4%** (31.0% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 60**. An RSI of 60 is neutral.
- **Beta (1 yr): 2.88** (volatility 72%). Beta of 2.88 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RXRX · Page: https://foliofundamentals.com/stocks/rxrx

Not investment advice.